Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

299 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase I clinical and magnetic resonance imaging study of the vascular agent NGR-hTNF in patients with advanced cancers (European Organization for Research and Treatment of Cancer Study 16041).
van Laarhoven HW, Fiedler W, Desar IM, van Asten JJ, Marréaud S, Lacombe D, Govaerts AS, Bogaerts J, Lasch P, Timmer-Bonte JN, Lambiase A, Bordignon C, Punt CJ, Heerschap A, van Herpen CM. van Laarhoven HW, et al. Among authors: lambiase a. Clin Cancer Res. 2010 Feb 15;16(4):1315-23. doi: 10.1158/1078-0432.CCR-09-1621. Epub 2010 Feb 9. Clin Cancer Res. 2010. PMID: 20145168 Free article. Clinical Trial.
Factors affecting the unexpected failure of DCE-MRI to determine the optimal biological dose of the vascular targeting agent NGR-hTNF in solid cancer patients.
Desar IM, van Herpen CM, van Asten JJ, Fiedler W, Marreaud S, Timmer-Bonte JN, ter Voert EG, Lambiase A, Bordignon C, Heerschap A, van Laarhoven HW. Desar IM, et al. Among authors: lambiase a. Eur J Radiol. 2011 Dec;80(3):655-61. doi: 10.1016/j.ejrad.2010.08.045. Epub 2010 Sep 21. Eur J Radiol. 2011. PMID: 20863638
Phase Ib study of NGR-hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours.
Gregorc V, Santoro A, Bennicelli E, Punt CJ, Citterio G, Timmer-Bonte JN, Caligaris Cappio F, Lambiase A, Bordignon C, van Herpen CM. Gregorc V, et al. Among authors: lambiase a. Br J Cancer. 2009 Jul 21;101(2):219-24. doi: 10.1038/sj.bjc.6605162. Epub 2009 Jun 30. Br J Cancer. 2009. PMID: 19568235 Free PMC article. Clinical Trial.
Phase I study of NGR-hTNF, a selective vascular targeting agent, in combination with cisplatin in refractory solid tumors.
Gregorc V, De Braud FG, De Pas TM, Scalamogna R, Citterio G, Milani A, Boselli S, Catania C, Donadoni G, Rossoni G, Ghio D, Spitaleri G, Ammannati C, Colombi S, Caligaris-Cappio F, Lambiase A, Bordignon C. Gregorc V, et al. Among authors: lambiase a. Clin Cancer Res. 2011 Apr 1;17(7):1964-72. doi: 10.1158/1078-0432.CCR-10-1376. Epub 2011 Feb 9. Clin Cancer Res. 2011. PMID: 21307147 Clinical Trial.
Defining the optimal biological dose of NGR-hTNF, a selective vascular targeting agent, in advanced solid tumours.
Gregorc V, Citterio G, Vitali G, Spreafico A, Scifo P, Borri A, Donadoni G, Rossoni G, Corti A, Caligaris-Cappio F, Del Maschio A, Esposito A, De Cobelli F, Dell'Acqua F, Troysi A, Bruzzi P, Lambiase A, Bordignon C. Gregorc V, et al. Among authors: lambiase a. Eur J Cancer. 2010 Jan;46(1):198-206. doi: 10.1016/j.ejca.2009.10.005. Eur J Cancer. 2010. PMID: 19900802 Clinical Trial.
Phase I and pharmacodynamic study of high-dose NGR-hTNF in patients with refractory solid tumours.
Zucali PA, Simonelli M, De Vincenzo F, Lorenzi E, Perrino M, Bertossi M, Finotto R, Naimo S, Balzarini L, Bonifacio C, Timofeeva I, Rossoni G, Mazzola G, Lambiase A, Bordignon C, Santoro A. Zucali PA, et al. Among authors: lambiase a. Br J Cancer. 2013 Jan 15;108(1):58-63. doi: 10.1038/bjc.2012.506. Epub 2012 Nov 20. Br J Cancer. 2013. PMID: 23169299 Free PMC article. Clinical Trial.
Phase II study of NGR-hTNF in combination with doxorubicin in relapsed ovarian cancer patients.
Lorusso D, Scambia G, Amadio G, di Legge A, Pietragalla A, De Vincenzo R, Masciullo V, Di Stefano M, Mangili G, Citterio G, Mantori M, Lambiase A, Bordignon C. Lorusso D, et al. Among authors: lambiase a. Br J Cancer. 2012 Jun 26;107(1):37-42. doi: 10.1038/bjc.2012.233. Epub 2012 May 29. Br J Cancer. 2012. PMID: 22644293 Free PMC article. Clinical Trial.
Phase II study of NGR-hTNF, a selective vascular targeting agent, in patients with metastatic colorectal cancer after failure of standard therapy.
Santoro A, Rimassa L, Sobrero AF, Citterio G, Sclafani F, Carnaghi C, Pessino A, Caprioni F, Andretta V, Tronconi MC, Finocchiaro G, Rossoni G, Zanoni A, Miggiano C, Rizzardi GP, Traversari C, Caligaris-Cappio F, Lambiase A, Bordignon C. Santoro A, et al. Among authors: lambiase a. Eur J Cancer. 2010 Oct;46(15):2746-52. doi: 10.1016/j.ejca.2010.07.012. Epub 2010 Aug 12. Eur J Cancer. 2010. PMID: 20708923 Clinical Trial.
Phase II study of asparagine-glycine-arginine-human tumor necrosis factor alpha, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma.
Gregorc V, Zucali PA, Santoro A, Ceresoli GL, Citterio G, De Pas TM, Zilembo N, De Vincenzo F, Simonelli M, Rossoni G, Spreafico A, Grazia Viganò M, Fontana F, De Braud FG, Bajetta E, Caligaris-Cappio F, Bruzzi P, Lambiase A, Bordignon C. Gregorc V, et al. Among authors: lambiase a. J Clin Oncol. 2010 May 20;28(15):2604-11. doi: 10.1200/JCO.2009.27.3649. Epub 2010 Apr 20. J Clin Oncol. 2010. PMID: 20406925 Clinical Trial.
Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma.
Santoro A, Pressiani T, Citterio G, Rossoni G, Donadoni G, Pozzi F, Rimassa L, Personeni N, Bozzarelli S, Rossoni G, Colombi S, De Braud FG, Caligaris-Cappio F, Lambiase A, Bordignon C. Santoro A, et al. Among authors: lambiase a. Br J Cancer. 2010 Sep 7;103(6):837-44. doi: 10.1038/sj.bjc.6605858. Epub 2010 Aug 17. Br J Cancer. 2010. PMID: 20717115 Free PMC article. Clinical Trial.
299 results